Odalasvir

N/A

Report date: 2023/05/07 20:00:22
NME

Base Information

Drug NameOdalasvir
Drug Alias NameResistance-focussed HCV programme奥拉司韦奥达拉韦ACH-3102JNJ-64289901 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNonstructural protein 5A inhibitors
TargetsNonstructural protein 5A
Therapy Area/IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAchillion Pharmaceuticals IncJanssen Pharmaceutical Kk
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Pharmaceutical KkAlexion Pharmaceuticals IncJanssen Research & Development Llc +[4] 
Active IndicationsN/A
Inactive IndicationsRenal InsufficiencyHepatic InsufficiencyHepatitis C, Chronic +[4] 

Other Information

ATC CodeN/A
Related LinksWikipedia